Human Immunodeficiency Virus | Current Treatment | US | 2016

launch Related Market Assessment Reports

• Renal Cell Carcinoma – Current Treatment – Detailed, Expanded Analysis: Treatment Sequencing (US)

  June 2023

  Key benefits and uses

  Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.

  Drill down into physicians’ treatment sequences and understand who to position…

• Special Topics | Comorbidities in Major Depressive Disorder | US

  Disorders such as anxiety, substance use disorder, and insomnia frequently coexist with major depressive disorder (MDD) and present treatment challenges to psychiatrists and primary care…

• Venous Thromboembolism – Landscape & Forecast – Disease Landscape & Forecast

  June 2023

  Copy/Paste the core content from the latest edited report brochure. DELETE the “Market Outlook” header from the top.

  Venous thromboembolism (VTE) is the obstruction of a vein caused by a…

• Vitiligo – Executive Insights – Executive Insights (US)

  May 2023

  Vitiligo is a chronic skin depigmentation disorder characterized by the destruction or loss of function of melanocytes. Its etiology and pathophysiology are not well understood but are believed to…

• Dry Eye – Access & Reimbursement – Detailed, Expanded Analysis (US)

  For more than a decade, AbbVie’s Restasis was the only FDA-approved therapy for dry eye disease (DED) until the launch of Novartis’s Xiidra in 2016, followed by Restasis MultiDose, Sun…